Medical Condition News

RSS

Hydrophobic proteins may serve as biomarkers for treating colorectal cancer

Colorectal cancer, cancer of the colon and rectum, is a common cause of mortality worldwide. Statistical data showed that the number of deaths caused by colorectal cancer is increasing in both men and women.

25 Jun 2010

$Repetitive impact on feet can increase risk of stress fractures$

Repetitive impact on feet can increase risk of stress fractures

Stress fractures of the foot are becoming more common in runners, especially first-time marathoners, according to the American College of Foot and Ankle Surgeons.

25 Jun 2010

Cardio-respiratory aerobic exercise reduces joint pain in RA patients

Researchers from the University of Grenoble Medical School in France determined that cardio-respiratory aerobic exercise is safe for patients with stable rheumatoid arthritis (RA).

25 Jun 2010

Majority of older women seek help for eating disorders

Eating disorders are equal-opportunity offenders – crossing economic and cultural boundaries and leaping the borders of age and gender. For a long time thought to be diseases affecting teens and young women in their 20s, eating disorder treatment centers nationwide are seeing an increase in the population of older women seeking help for eating disorders.

25 Jun 2010

Cognitive behaviour therapy effective for treating anxiety disorders

Brief therapy at the GP's surgery can effectively treat anxiety and depression. Researchers writing in the open access journal BMC Medicine found that cognitive behaviour therapy (CBT) was effective for treating anxiety disorders, while CBT, problem solving therapy (PST) and counseling were all equally effective in treating depression and mixed anxiety and depression.

25 Jun 2010

CXCL12/CXCR4 chemokine axis plays a critical role in pathogenesis of ulcerative colitis

Ulcerative colitis (UC) is characterized by frequent diarrheal attacks and anal bleeding. Histologic characteristics of UC are the invasion of the crypt epithelium and lamina propria by peripheral blood mononuclear cells (PBMCs), disruption of the epithelial lining, and consequently mucosal ulceration and crypt abscess formation in the bowel wall.

25 Jun 2010

Gene therapy holds promise in treating cancer, cardiovascular and neurodegenerative diseases

EUREKA project E! 3371 Gene Transfer Agents has made great advances in the development of novel non-viral carriers able to introduce genetic material into the target cells.

25 Jun 2010

Nintendo DS helps cure lazy eye

For six year old Ben Michaels nothing could be more welcome than his recent therapy regime. He was detected with a problem in his eyesight by a school nurse from the age of four. On examination he was found to have a lazy right eye or amblyopia. Left untreated it would have lost him his vision completely.

24 Jun 2010

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Neogenix Oncology announced today that it has filed a patent application with the US Patent and Trade Office for the NPC-1C antigen. This antigen appears to be tumor specific for pancreatic and colorectal tumors.

24 Jun 2010

University of Michigan professor recognised with PHA Award of Excellence

The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc., today announced Dr. Vallerie McLaughlin of the University of Michigan Health System as the recipient of the annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. As part of the award, the University of Michigan System will receive a grant in the amount of $50,000 to support continued excellence in care for patients with PAH.

24 Jun 2010

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

24 Jun 2010

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Tethys Bioscience, Inc., a privately held company, announced today that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.

24 Jun 2010

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Nektar Therapeutics announced today that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company's lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers. The study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio.

24 Jun 2010

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

MDS Nordion, a leading provider of products and services to the global health science market, Guerbet, a pharmaceutical group specialized in medical imaging, and Cyceron, a biomedical imaging centre in France, announced today they have entered into an agreement to develop new Positron Emission Tomography (PET) radiotracers for cancer diagnostics.

24 Jun 2010

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.

24 Jun 2010

Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies. This multi-center study is the second clinical trial of IPI-493, Infinity's oral heat shock protein 90 (Hsp90) chaperone inhibitor.

24 Jun 2010

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

St. Luke's Episcopal Hospital (St. Luke's) joins John Goss, M.D., in celebrating his milestone as he recently performed his 1,000th liver transplantation procedure. The largest liver transplant program in Houston's world-renowned Texas Medical Center, St. Luke's performs approximately 75 liver transplants annually. Additionally, St. Luke's liver transplant survival rate is the highest in the nation, with a one-year adult patient survival rate of 96.5 percent compared to the national expected survival rate of 89.38 percent.

24 Jun 2010

Inhalation of gaseous hydrogen sulfide can reduce or prevent lung injury associated with mechanical ventilation

A study appearing in the July 2010 issue of Anesthesiology is the first to show that inhalation of gaseous hydrogen sulfide can reduce or even prevent lung injury in critical care situations that require mechanical ventilation.

24 Jun 2010

Individuals get involved in alcohol or drug related accidents during summer holidays

As the days grow longer and hotter, some chemical dependency professionals have their own name for summer: substance abuse season, because that's when individuals who abuse or are addicted to alcohol, prescription medications and drugs get involved in alcohol or drug related accidents during the summer holidays.

24 Jun 2010

Blood flow disturbances in artery determine appearance of atherosclerosis: Study

A new animal model of atherosclerosis has allowed researchers to identify a host of genes turned on or off during the initial stages of the process, before a plaque appears in the affected blood vessel.

24 Jun 2010

Medical Condition News

Hydrophobic proteins may serve as biomarkers for treating colorectal cancer

Repetitive impact on feet can increase risk of stress fractures

Cardio-respiratory aerobic exercise reduces joint pain in RA patients

Majority of older women seek help for eating disorders

Cognitive behaviour therapy effective for treating anxiety disorders

CXCL12/CXCR4 chemokine axis plays a critical role in pathogenesis of ulcerative colitis

Gene therapy holds promise in treating cancer, cardiovascular and neurodegenerative diseases

Nintendo DS helps cure lazy eye

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

University of Michigan professor recognised with PHA Award of Excellence

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

Inhalation of gaseous hydrogen sulfide can reduce or prevent lung injury associated with mechanical ventilation

Individuals get involved in alcohol or drug related accidents during summer holidays

Blood flow disturbances in artery determine appearance of atherosclerosis: Study

Extending the reach of Amperia™

Modular cleanrooms: Enhancing flexibility and compliance

Redefining control and consistency in anaerobic microbiome workflows

Latest News